US 11,752,114 B2
Transdermal therapeutic system
Florian Hammes, Andernach (DE); Tobias Kleudgen, Ettringen (DE); and Anja Tomeleri, Neuwied (DE)
Assigned to LTS Lohmann Therapie-Systeme AG, Andernach (DE)
Filed by LTS LOHMANN Therapie-Systeme AG, Andernach (DE)
Filed on Apr. 17, 2019, as Appl. No. 16/386,458.
Prior Publication US 2020/0330404 A1, Oct. 22, 2020
Int. Cl. A61K 31/135 (2006.01); A61K 9/70 (2006.01); A61P 25/24 (2006.01)
CPC A61K 31/135 (2013.01) [A61K 9/7084 (2013.01); A61K 9/7053 (2013.01); A61P 25/24 (2018.01)] 8 Claims
 
1. A transdermal therapeutic system comprising a backing layer which is not permeable for the active ingredient, and at least one matrix layer on one side of the backing layer, wherein the matrix layer includes at least one pressure sensitive adhesive comprising an acrylic copolymer including free hydroxyl groups and no free carboxyl groups, and (S)-ketamine or a pharmaceutically acceptable salt or solvate thereof, and a penetration enhancer comprising a mixture of levulinic acid and methyl laurate, wherein the matrix layer has an area weight of 100 to 275 g/m2, wherein the methyl laurate is present in an amount greater than the levulinic acid, and wherein the weight ratio of levulinic acid to methyl laurate is between about 1:1.66 and 1:1.68.